Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies. Notably, many targeted therapies are intended for patients with activating EGFR mutations, which are more prevalent in China than in the Western markets. We expect China’s NSCLC therapy market to experience robust growth throughout the 2021-2031 forecast period. The key drivers of this market growth will be the continued uptake of targeted and biomarker-driven therapies, including immune checkpoint inhibitors, EGFR inhibitors, and ALK inhibitors. The incorporation of several of these therapies in China’s National Reimbursement Drug List (NRDL) will secure better patient access. Moreover, several targeted therapies are expected to be approved within the forecast period, which will result in increased therapy options and market growth.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 medical oncologists.
Diagnosed incidence of non-small-cell lung cancer (NSCLC) in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient share of key NSCLC therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: > 20 drugs. Phase II: 20+ drugs. Coverage of select early-phase products.